Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus usual care for reversal of neuromuscular blockade in orthopedic surgery patients receiving thromboprophylaxis
2011-001201-27Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sugammadex and neostigmine (2 arms), sponsored by Merck & Co. Primary endpoint: Adjudicated post-surgical bleeding events. Started Aug 2011; status: completed.
02
Drugs
Sugammadexneostigmine
Beyond the preview
Go deeper on 2011-001201-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001201-27.